ENYO Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
33
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$42.6M
- Investors
-
9
ENYO Pharma General Information
Description
Operator of a clinical-stage biotechnology company intended to develop drug candidates by mimicking virus strategies to modulate host cellular functions. The company provides small molecule therapeutics based on fibrinolytic and anti-inflammatory properties, in various areas with unmet medical needs as well as offers a drug discovery engine, enabling healthcare professionals to avail therapeutics to treat rare kidney disease Alport syndrome, and chronic liver diseases.
Contact Information
Website
www.enyopharma.comCorporate Office
- Bioserra 1 Bâtiment B
- 60 Avenue Rockefeller
- 69008 Lyon
- France
Corporate Office
- Bioserra 1 Bâtiment B
- 60 Avenue Rockefeller
- 69008 Lyon
- France
ENYO Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series C) | 03-Jan-2024 | $42.6M | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC | 02-Dec-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series B) | 04-Jun-2018 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 06-Dec-2016 | Completed | Startup | |||
| 2. Early Stage VC (Series A) | 03-Feb-2016 | $23.9M | $26.7M | Completed | Startup | |
| 1. Seed Round | 01-Jan-2015 | $2.76M | $2.76M | Completed | Startup |
ENYO Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Ordinary Shares | 16,021 | $1.185910 | $166.18 | $166.18 | 1x | $166.18 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
ENYO Pharma Comparisons
Industry
Financing
Details
ENYO Pharma Competitors (59)
One of ENYO Pharma’s 59 competitors is Centrose, a Venture Capital-Backed company based in Middleton, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Middleton, WI | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Alphina Therapeutics | Venture Capital-Backed | New Haven, CT | ||||
| Citryll | Venture Capital-Backed | Oss, Netherlands | ||||
| NeRRe Therapeutics | Venture Capital-Backed | Stevenage, United Kingdom |
ENYO Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ENYO Pharma Patents
ENYO Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12030861-B1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Active | 13-Jul-2023 | ||
| US-20250019358-A1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 13-Jul-2023 | ||
| US-20250019370-A1 | L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof | Pending | 13-Jul-2023 | ||
| CA-3213217-A1 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment | Pending | 28-Apr-2021 | ||
| EP-4329761-A1 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment | Pending | 28-Apr-2021 | A61K31/496 |
ENYO Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ENYO Pharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Large Ventures | Venture Capital | Minority | ||
| Andera Partners | PE/Buyout | Minority | ||
| OrbiMed | Growth/Expansion | Minority | ||
| Sofimac Innovation | Venture Capital | Minority | ||
| Horizon 2020 | Government |
ENYO Pharma FAQs
-
When was ENYO Pharma founded?
ENYO Pharma was founded in 2014.
-
Where is ENYO Pharma headquartered?
ENYO Pharma is headquartered in Lyon, France.
-
What is the size of ENYO Pharma?
ENYO Pharma has 33 total employees.
-
What industry is ENYO Pharma in?
ENYO Pharma’s primary industry is Drug Discovery.
-
Is ENYO Pharma a private or public company?
ENYO Pharma is a Private company.
-
What is ENYO Pharma’s current revenue?
The current revenue for ENYO Pharma is .
-
How much funding has ENYO Pharma raised over time?
ENYO Pharma has raised $128M.
-
Who are ENYO Pharma’s investors?
Large Ventures, Andera Partners, OrbiMed, Sofimac Innovation, and Horizon 2020 are 5 of 9 investors who have invested in ENYO Pharma.
-
Who are ENYO Pharma’s competitors?
Centrose, NexImmune, Alphina Therapeutics, Citryll, and NeRRe Therapeutics are some of the 59 competitors of ENYO Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
